Acknowledgement

This activity is provided by Talem Health and ACCESS Oncology.


This online program is recorded content from the live session at Oncology Congress Spring 2026 and is co-supported by independent educational grants from AbbVie, Inc.; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; GSK; and Johnson & Johnson. This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Credit Available

• Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
• Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
• Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for oncologists and other health professionals practicing in community settings, including those who serve geographically diverse populations.

Program Overview

In recent years, the PI3K/AKT/PTEN pathway has emerged as an important player in breast cancer development. Up to 50% of patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2-) breast cancer have actionable biomarkers within this pathway, paving the way for novel approaches to management. In this online, on-demand CME/CE activity, expert faculty will review available and emerging therapies targeting the PI3K/AKT/PTEN pathway, including the latest clinical trial data. The program will also highlight strategies for managing treatment-related adverse events and the role of the multidisciplinary team in improving care coordination, treatment adherence, and outcomes for patients in community-based settings. 

This enduring activity is a recorded session from Oncology Congress that took place on June 13, 2026.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Describe the clinical significance of PI3K/AKT/PTEN pathway alterations in breast cancer and the mechanisms of action of therapies that target this pathway 
• Evaluate the efficacy and safety of therapies targeting the PI3K/AKT/PTEN pathway in advanced HR+/HER2- breast cancer
• Integrate evidence-based strategies to identify, monitor, and manage adverse events associated with PI3K/AKT/PTEN pathway–targeted therapies in community practice settings
• Apply team-based care strategies within community oncology settings to improve coordination, treatment adherence, and outcomes for patients with breast cancer

Faculty

Laura M. Spring, MD 
Assistant Professor of Medicine 
Harvard Medical School 
Attending Physician, Medical Oncology 
Massachusetts General Hospital Cancer Center 
Boston, MA

Chris Prakash, MD 
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
Past President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris 
Paris, TX

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-26-081-H01-P)
Type of Activity: Application

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty

Laura M. Spring, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., Eli Lilly and Company, Gilead Sciences, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Precede Biosciences, and Seagen, Inc.; research/grant support (awarded to institution) from AstraZeneca Pharmaceuticals, Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., Greenwich LifeSciences, Inc., and Merck & Co., Inc. 

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer 

None of the Talem Health staff (planners, managers, or reviewer) for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

1. Read the CME/CE information, including learning objectives and disclosure statements.
2. Complete the pre-test.
3. View the online activity.
4. Complete the post-test and evaluation form.

A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements 

Supported Browsers: 
Desktop/laptop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome

Supported Phones & Tablets: 
All devices

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

©ACCESS Oncology, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited. 

Media 

Internet activity 

Fee Information 

There is no fee for this educational activity. 

Contact Information 

For questions about this activity, please contact ACCESS Oncology (a division of Talem Health) at 800-913-9370 or cme@accessoncologyce.com.